(MMI), a robotics company dedicated to increasing treatment options and improving clinical outcomes for patients with complex ...

Annette Slyman, Chief Operating Officer, Life Backup Plan by Galacxia, Inc ...

Company to Showcase Progress on Radical Catheter Portfolio and Best-in-Class Ribbon Technology Platform at Society of Neurointerventional Surgery Annual Meeting. LOS GATOS, calif.

Lisaftoclax is a proprietary, novel orally administered small-molecule Bcl-2 selective inhibitor developed by Ascentage Pharma to treat patients with malignancies by selectively blocking the ...

Goldman Sachs & Co. LLC, Guggenheim Securities, TD Cowen, Cantor and Oppenheimer & Co. are acting as joint book-running managers for the public offering.

Additionally, a webcast replay of the conference call will be available on the Investors section of the Company’s website following the call. Dentsply Sirona is the world’s largest diversified ...

BOWIE, Md., July 10, 2025 (GLOBE NEWSWIRE) -- The Epilepsy Foundation of America (EFA) is proud to announce the appointment of Daryl Drabinsky, distinguished communications and corporate affairs ...

Title: Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy: An Integrated Safety Analysis Presenter: Ahmad Masri, M.D., MS, Director of the Hypertrophic Cardiomyopathy Center at Oregon ...

Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to address unmet needs of those living with bradykinin-mediated diseases such ...

The North Central London expansion will bring HealthTab™ to even more patients, with a continued focus on underserved populations and reducing health disparities. By expanding access to preventative ...

The USAN Council has adopted zervimesine as the United States Adopted Name (USAN) for CT1812.

The Oncogenic Flip in Patients with Leptomeningeal Metastatic Disease (LMD): Longitudinal Detection in Cerebrospinal Fluid Tumor Cells (CSF-TCs) Reveals Implications for Differential Treatment of the ...